TLSI trades 96.6% below Wall Street's consensus target of $8.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes TLSI achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 3 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 8, 2026, TriSalus Life Sciences, Inc. (TLSI) has a Wall Street consensus price target of $8.00, based on estimates from 3 covering analysts. With the stock currently trading at $4.07, this represents a potential upside of +96.6%. The company has a market capitalization of $154M.
Analyst price targets range from a low of $8.00 to a high of $8.00, representing a 0% spread in expectations. The median target of $8.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 3 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, TLSI trades at a trailing P/E of -2.2x. Analysts expect EPS to grow +38.3% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
NVCRNovoCure Limited | $2.0B | $17.72 | $33.00 | +86.2% | Buy | — | 15 |
ANGOAngioDynamics, Inc. | $540M | $13.07 | $16.50 | +26.2% | Hold | — | 11 |
IRTCiRhythm Technologies, Inc. | $4.1B | $125.09 | $188.75 | +50.9% | Buy | — | 20 |
INVAInnoviva, Inc. | $1.6B | $22.25 | $37.00 | +66.3% | Buy | 6.2x | 10 |
CNMDCONMED Corporation | $1.1B | $34.24 | $78.00 | +127.8% | Hold | 7.8x | 21 |
ATRCAtriCure, Inc. | $1.7B | $32.80 | $51.33 | +56.5% | Buy | 926.6x | 19 |
BMYBristol-Myers Squibb Company | $118.4B | $57.97 | $62.60 | +8.0% | Hold | 9.2x | 41 |
MRKMerck & Co., Inc. | $318.3B | $128.86 | $133.77 | +3.8% | Buy | 25.1x | 37 |
REGNRegeneron Pharmaceuticals, Inc. | $70.3B | $676.23 | $836.00 | +23.6% | Buy | 14.6x | 48 |
BSXBoston Scientific Corporation | $67.3B | $45.30 | $82.40 | +81.9% | Buy | 13.5x | 44 |
Quick answers to the most common questions about buying TLSI stock.
The consensus Wall Street price target for TLSI is $8, representing 96.6% upside from the current price of $4.07. With 3 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
TLSI has a consensus rating of "Buy" based on 3 Wall Street analysts. The rating breakdown is predominantly bullish, with 3 Buy/Strong Buy ratings. The consensus 12-month price target of $8 implies 96.6% upside from current levels.
TLSI's current price is $4.07 with a consensus target of $8 (96.6% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $8 for TLSI, while the most conservative target is $8. The consensus of $8 represents the median expectation. These targets typically reflect 12-month expectations.
TLSI is lightly followed, with 3 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month TLSI stock forecast based on 3 Wall Street analysts shows a consensus price target of $8, with estimates ranging from $8 (bear case) to $8 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on TLSI, with a "Buy" consensus rating and $8 price target (96.6% upside). 3 of 3 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
TLSI analyst price targets range from $8 to $8, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $8 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.